November 22, 2010 10:08 ET

Monoclonal Antibodies Market Grew 13% in 08-09

ROCKVILLE, MD--(Marketwire - November 22, 2010) - has announced the addition of RNCOS's new report "Global Monoclonal Antibody Market Analysis" to their collection of Biotechnology market reports. For more information, visit

Considered as an indispensable tool in the clinical and biotechnology sector, monoclonal antibodies have testified to be useful in the diagnosis and treatment of many infectious, immune, and neoplastic diseases along with its application in the study of pathogen-host interactions and dialing, detection, & quantification of different molecules.

The presence of monoclonal antibodies therapeutics has changed the face of modern medicine in the past decade as they provide innovative and effective therapies for numerous previously refractory illnesses. The number of monoclonal antibodies reaching the marketplace has exponentially increased over the past few years. Various factors such as rapid uptake of monoclonal antibodies, expansion of patient base due to the drug approvals received, and no generics for biological therapies have driven the optimistic market performance of this industry.

According to our new research report "Global Monoclonal Antibody Market Analysis", the global monoclonal antibodies market witnessed an annual growth rate of around 13% during 2008-2009. Presently, large pharmaceutical companies are investing heavily both in developing such drugs internally and acquiring monoclonal antibody candidates from other companies. The inherent specificity and predictability of monoclonal antibodies that reduces the time period of drug development and increases rate of success in preclinical and clinical trials, relative to non-biological 'small molecule' drugs, is further boosting the growth of the industry.

Our report has found that the market is presently dominated by Oncology and AIID applications. However, therapeutic applications of monoclonal antibodies are extending to new therapy areas such as CNS disorders and metabolic disorders. In addition, smaller companies are likely to become more visible as their products move closer to regulatory approvals.

For more information, visit

Contact Information